Neumora Therapeutics is trading 5.5% down at $1.56 in pre-market sessions, likely reflecting a light-liquidity adjustment in the absence of fresh catalysts.
- The stock has declined from its previous closing price of $1.65.
- No company-specific headlines, earnings, FDA updates, or analyst ratings have been issued this morning.